...
首页> 外文期刊>Bulletin of experimental biology and medicine >Expression of molecular markers in the tumor and survival prognosis in osteosarcoma.
【24h】

Expression of molecular markers in the tumor and survival prognosis in osteosarcoma.

机译:分子标志物在肿瘤中的肿瘤和存活预后的表达。

获取原文
获取原文并翻译 | 示例

摘要

Immunohistochemical study of p53, VEGF, Flt-1/VEGFR1 Ab-1, EGFR, HER-2/neu, Bax, and Cox-2 expression in osteosarcomas was carried out in 40 patients aged 16-70 years. Expression of p53 was detected in 27.5% tumors, VEGF in 15%, Flt-1/VEGFR1 Ab-1 in 97.5%, EGFR in 52.5%, HER-2/neu in 32.5%, Bax in 77.8%, and Cox-2 in 32.3% tumors. Multifactorial analysis showed that the expression of HER-2/neu (p=0.004), p53 (p=0.01), and Cox-2 (p=0.04) in osteosarcomas significantly correlated with unfavorable prognosis for overall survival, while HER-2/neu (p=0.02) and Cox-2 (p=0.003) with relapse-free survival. Analysis of HER-2/neu, p53, and Cox-2 expression in the primary tumor should be taken into consideration in the treatment of patients with osteosarcoma.
机译:在16-70岁的40岁患者中进行了P53,VEGF,FLT-1 / VEGFR1 AB-1,EGFR,HER-2 / NEU,BAX和COX-2表达的免疫组化研究。 在27.5%肿瘤中检测到P53的表达,VEGF为15%,FLT-1 / VEGFR1 AB-1在97.5%,EGFR中的52.5%,HER-2 / Neu,32.5%,BAX为77.8%,COX-2 在32.3%的肿瘤中。 多因素分析表明,骨质肉瘤中HER-2 / NEU(P = 0.004),P53(P = 0.01)和COX-2(P = 0.04)的表达与整体生存期的不利预后显着相关,而她-2 / Neu(P = 0.02)和COX-2(P = 0.003),无复发存活。 在治疗骨肉瘤患者时,应考虑到原发性肿瘤中HER-2 / NEU,P53和COX-2表达的分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号